Individualizing therapy - In search of approaches to maximize the benefit of drug treatment (II)

Current Controlled Trials in Cardiovascular Medicine

Volumn 5, Issue , 2004, Pages

  Pater, Cornel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; DNA; DRUG METABOLIZING ENZYME; FLUCONAZOLE; METRONIDAZOLE; MICONAZOLE; WARFARIN;

BIOEQUIVALENCE; CLINICAL PRACTICE; DNA SEQUENCE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; GENETIC REGULATION; HUMAN; INDIVIDUALIZATION; PHARMACEUTICAL CARE; PHENOTYPIC VARIATION; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; TREATMENT PLANNING;

EID: 27544511769     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-5-7     Document Type: Review

References (46)

1. Wuth O: Rational bromide treatment: new methods for its control. JAMA 1927, 88:2031-2017.
2. Shannon JA: The study of antimalarials and antimalarial activity in human malarias. Harvey Lectures Series 1946, 41:43-8.
3. Buchchal F, Svensmark O, Schiller PJ: Clinical and electroencephalographic correlation with serum levels of diphenylhydantoin. Arch Neurol 1960, 2:624-63.
4. Grahame-Smith DG, Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J 1969, 1:826-829.
5. Kalow W: Pha macogenetics: heredity and response to drugs. Philadelphia: Saunders 1962.
6. Reidenberg MM, ed: Individualization of drug therapy. Med Clin North Am 1974, 58:905-116.
7. Vasquez EM, Min DI: Transplant pharmacists' opinions on generic product selection of critical-dose drugs. Am J Health Syst Pharm 1999, 56:615-21.
8. Banahan BF III, Kolassa EM: A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med 1997, 157:2080-208.
9. Kessler KM, Kessler DK: Definitions and axioms of net treatment benefit. Clin Pharmacol Ther 2001, 69(1):1-6.
10. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988, 318:1728-3.
11. Naylor CD, Chen E, Strauss B: Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992, 117:916-21.
12. McQuay HJ, Moore RA: Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997, 126:712-20.
13. Shargel L, Yu ABC: 1985 Applied Biopharmaceutics and Pharmacokinetics,. 2nd edition. Appleton-Century-Crofts, NorwalK, CT:129-131.
14. Bioavailability and Bioequivalence Requirements. 21 CFR § 2001, 320:1-63.
15. Skelly JP: Bioavailability and bioequivalence. J Clin Pharmacol 1976, 16(10 pt 2):539-45.
16. Patnaik R, Lesko LJ, Chan K, Williams RL: Bioequivalence assessment of generic drugs: an American point of view. Eur J Drug Metab Pharmacokinet 1996, 21:159-64.
17. Federal Register: Drug Products, Bioequivalence Requirements and in vivo Bioavailability Procedures,. 1997, 42(5):1634-5.
18. Anderson S: Individual Bioequivalence: A Problem of Switchability. Biopharmaceutical Reports 1993, 2(2):1-11.
19. Lamy PP: Generic equivalents: issues and concerns. J Clin Pharmacol 1986, 26:309-16.
20. Steinijans VW, Hauschke D, Jonkman JHG: Controversies in bioequivalence studies. Clin Pharmacokinet 1992, 22:247-53.
21. Metzler CM: Bioavailability/bioequivalence: study design and statistical issues. J Clin Pharmacol 1989, 29:289-92.
22. Blume HH, Midha KK: BIO-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1993, 82:1186-9.
23. Welage LS, Kirking DM, Ascione FJ, Gaither CA: Understanding the scientific issues embedded in the generic drug approval rocess. J Am Pharm Assoc (Wash) 2001, 41(6):856-867.
24. Hauck WW, Anderson S: Types of bioequivalence and related statistical considerations. Int J Clin Pharmacol Ther Toxicol 1992, 30:181-7.
25. Endrenyi L: A method for the evaluation of individual bioequivalence. Int J Clin Pharmacol Their 1994, 32:497-508.
26. Guidance for industry: statistical approaches to establishing bioequivalence Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration 2001 [http://www.fda.gov/cder/guidance/3616fnl.htm].
27. Shuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987, 15:657-80.
28. Meredith PA, Elliot HL, Donnelly R, Reid JL: Dose-response clarification in early drug development. J Hypertens Suppl 1991, 9:S356-S357.
29. Meredith PA: Generic drugs. Therapeutic equivalence. Drug Saf 1996, 15:233-42.
30. Henderson JD: Current issues in bioequivalence determination. Appl Clin Trials 1992, 1:44-9.
31. Riley TN, Ravis WR: Key concepts in drug bioequivalence. US Pharmacist 1987:40-53.
32. Mishra B, Bhattacharya SK: The bioavailability of drugs. Natl Med J India 1993, 6(2):85-8.
33. Blacke MI: Drug product equivalency. Part 2. Drug Topics 1988:84-91.
34. Nation RL, Sansom LN: Bioequivalence requirements for generic products. Pharmacol Ther 1994, 62:41-55.
35. Hauschke D, Steinijans WV, Diletti E, Schall R, Luus HG, Elze M, Blume H: Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalent studies. Int J Clin Pharmacol Ther 1994, 32:376-8.
36. Tsang YC, Pop R, Gordon P, Hems J, Spino, M: High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil. Pharm Res 1996, 13:846-50.
37. Buice RG, Subramanian VS, Duchin KL, Uko-Nne S: Bioequivalence of a highly variable drug: an experience with nadolol. Pharm Res 1996 13:1109-15.
38. Nolan P: Issues in bioequivalence and generic substitution. In: Amiodarone: From Lost Line to First Line Antiarrhythmic Therapy. Tampa, Fia: Cortex Communications 1999:31-5.
39. Schuetz EG, Wrighton SA, Barwick JL, Guzalian PS: Induction of cytochrome P-450 by glucocorticoids in rat liver. I. Evidence that glucocorticoids and pregnenolone 16 alpha-carbonitrile regulate de noro synthesis of a common form of cythocrome P-450 in cultures of adult rat hepatocytes and in the liver in vivo. J Biol Chem 1984, 259:1999-2006.
40. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF: Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996, 24:422-8.
41. O'Reilly RA: The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976, 295:354-7.
42. O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, Trager WF: Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992, 51:656-67.
43. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF: The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992, 51:398-407.
44. [http://www.tarowarfarin/arin.com/index_ch.asp?siteID=248].
45. Approved Drug Products with Therapeutic Equivalence Evaluations Rockville, Md. CDER, US, FDA 2000 http://www.fda.gov/cder/ob/default.htm].
46. Concept Paper: Premarketing Risk Assessment [http://http:/www.fda.gov/cder/guidance/5765dft.htm]. March 3, 2003.